Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: A prospective randomized trial

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 6, 2011, Pages 995-1000

  Bölükbas, Servet ^a   Eberlein, Michael ^b,c   Eckhoff, Jennifer ^a   Schirren, Joachim ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

COPD; NSCLC; RCT; Surgery

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; FORMOTEROL FUMARATE; TIOTROPIUM BROMIDE;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; BREATHING EXERCISE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG CANCER; LUNG FUNCTION TEST; MORNING DOSAGE; PILOT STUDY; PLETHYSMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; AIRWAY RESISTANCE; BRONCHODILATOR AGENTS; BUDESONIDE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PLETHYSMOGRAPHY, WHOLE BODY; PNEUMONECTOMY; PREOPERATIVE CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SMOKING CESSATION; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 79955618387     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.09.025     Document Type: Article

References (24)

1. Loganathan R.S., Stover D.E., Shi W., Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006, 129:1305-1312.
2. Congleton J., Muers M.F. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 1995, 89:291-296.
3. Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer independent of age, gender and smoking history. Eur Respir J 2009, 34(2):380-386.
4. Hill K., Goldstein R.S., Guyatt G.H., Blouin M., Tan W.C., Davis L.L., Heels-Ansdell D.M., Erak M., Bragaglia P.J., Tamari I.E., Hodder R., Stanbrook M.B. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010, 182(7):673-678.
5. Bednarek M., Maciejewski J., Wozniak M., Kuca P., Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008, 63(5):402-407.
6. Myerson J.S., Priest K., Power F., Ashley S., O'Brien M.E.R. Chronic obstructive pulmonary disease in lung cancer underdiagnosed and undertreated. Lung Cancer 2009, 63(Supplement 1):S24. 10.1016/S0169-5002(09)70074-1.
7. López-Encuentra A., Astudillo J., Cerezal J., Gonzalez-Aragoneses F., Novoa N., Sánchez-Palencia A. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg 2005, 27(1):8-13. Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).
8. Brunelli A., Charloux A., Bolliger C.T., Rocco G., Sculier J.P., Varela G., Licker M., Ferguson M.K., Faivre-Finn C., Huber R.M., Clini E.M., Win T., De Ruysscher D., Goldman L. ERS-ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and radiochemotherapy). Eur Respir J 2009, 34:17-41. on behalf of the European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy.
9. Markos J., Mullan B.P., Hillman D.R., Musk A.W., Antico V.F., Lovegrove F.T., Carter M.J., Finucane K.E. Preoperative assessment as a predictor and mortality and morbidity after lung resection. Am Rev Respir Dis 1989, 139:902-910.
10. Leo F., Venissac N., Pop D., Solli P., Filosso P., Minniti A., Radice D., Mouroux J., Spaggiari L., Pastorino U., Jougon J., Velly J.F., Oliaro A. Postoperative exacerbation of chronic obstructive pulmonary disease. Does it exist?. Eur J Cardiothorac Surg 2008, 33(3):424-429.
11. Lawrence V.A., Cornell J.E., Smetana G.W. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006, 144(8):596-608. American College of Physicians.
12. Tarhan S., Moffitt E.A., Sessler A.D., Douglas W.W., Taylor W.F. Risk of anesthesia and surgery in patients with chronic bronchitis and chronic obstructive pulmonary disease. Surgery 1973, 74:720.
13. Stein M., Cassara E.L. Preoperative pulmonary evaluation and therapy for surgery patients. JAMA 1970, 211:787.
14. Kobayashi S., Suzuki S., Niikawa H., Sugawara T., Yanai M. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology 2009, 14(5):675-679.
15. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., Yates J.C., Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789. TORCH investigators.
16. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
17. Mannino D.M., Aguayo S.M., Petty T.L., Redd S.C. Low lung function and incident lung cancer in the United States: data from the first national health and nutrition examination survey follow-up. Arch Intern Med 2003, 163:1475-1480.
18. Ueda K., Tanaka T., Hayashi M., Hamano K. Role of inhaled tiotropium on the perioperative outcomes of patients with lung cancer and chronic obstructive pulmonary disease. Thorac Cardiovasc Surg 2010, 58:38-42.
19. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554. UPLIFT Study Investigators.
20. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
21. Kardos P., Brutsche M., Buhl R., Gillissen A., Rabe K.F., Russi E.W., Sauer R., Worth H., Menz G. Combination of asthma and COPD: more frequent as considered to be?. Pneumologie 2006, 60:366-372.
22. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., Balter M., O'Donnell D., McIvor A., Sharma S., Bishop G., Anthony J., Cowie R., Field S., Hirsch A., Hernandez P., Rivington R., Road J., Hoffstein V., Hodder R., Marciniuk D., McCormack D., Fox G., Cox G., Prins H.B., Ford G., Bleskie D., Doucette S., Mayers I., Chapman K., Zamel N., FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8):545-555. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.
23. Halpin D. NICE guidance for COPD. Thorax 2004, 59(3):181-182.
24. Moller A.M., Villebro N., Pedersen T., Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002, 359(9301):114-117.